Liquidity is under pressure as the company continues to burn cash, with quarterly free cash flow outflows frequently exceeding $15 million and the current ratio compressing to 1.27.
| Cash from Operations | -51.94M | -60.29M | -56.19M | -32.61M | -40.6M | -42.88M | -18.62M | -9.54M |
| Operating CF Margin % | - | - | -2980.8% | -163.53% | -247.52% | - | - | - |
| Operating CF Growth % | 38.14% | -7.3% | -72.29% | 19.67% | 5.32% | -130.22% | -95.18% | - |
| Net Income | -56.27M | -60.82M | -70.52M | -37.37M | -53.81M | -49.98M | -15.04M | -10.25M |
| Depreciation & Amortization | 1.61M | 1.63M | 1.81M | 1.76M | 1.1M | 216K | 150K | 25K |
| Stock-Based Compensation | 3.01M | 6.25M | 8.83M | 8.01M | 7.4M | 4.09M | 632K | 559K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -117K |
| Other Non-Cash Items | 1.45M | 856K | 1.16M | 878K | 2.17M | 519K | -6.29M | 950K |
| Working Capital Changes | -1.73M | -8.21M | 2.53M | -5.89M | 2.54M | 2.28M | 1.92M | -711K |
| Change in Receivables | 0 | 0 | 1.35M | 5.58M | -6.93M | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 6.93M | 0 | 0 | 0 |
| Change in Payables | -1M | -7.5M | 3.46M | -4.33M | -883K | 1.01M | 0 | 116K |
| Cash from Investing | 0 | 0 | -254K | -769K | -3.61M | -498K | -560K | -266K |
| Capital Expenditures | 0 | 0 | -254K | -769K | -3.61M | -498K | -560K | -266K |
| CapEx % of Revenue | - | - | 13.47% | 3.86% | 22.02% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 6.03M | 6.03M | 13.08M | 58.43M | 15.91M | 109.43M | 93.86M | 21.91M |
| Debt Issued (Net) | 0 | 0 | -10M | 40M | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 2.75M | 6.03M | 23.58M | 18.33M | 15.74M | 111.6M | 0 | 22.1M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 3.27M | 0 | -496K | 100K | 166K | -2.17M | 93.86M | -193K |
| Net Change in Cash | -45.92M | -54.26M | -43.36M | 25.05M | -28.3M | 66.05M | 74.67M | 12.1M |
| Free Cash Flow | -51.94M | -60.29M | -56.44M | -33.38M | -44.21M | -43.37M | -19.18M | -9.81M |
| FCF Margin % | - | - | -2994.27% | -167.38% | -269.54% | - | - | - |
| FCF Growth % | 13.41% | -6.82% | -69.08% | 24.49% | -1.92% | -126.09% | -95.6% | - |
| FCF per Share | -1.05 | -1.29 | -1.29 | -0.94 | -1.53 | -2.35 | -0.67 | -0.34 |
| FCF Conversion (FCF/Net Income) | 0.92x | 0.99x | 0.80x | 0.87x | 0.75x | 0.86x | 1.25x | 0.87x |
| Interest Paid | 790K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical Trial Funding Gap
As reported in financial statements, the relationship between net income and operating cash flow remains tightly coupled, with the OCF/NI ratio fluctuating between 0.38 and 1.32, which suggests that non-cash adjustments like stock-based compensation are currently insufficient to mask the underlying cash-intensive nature of the business.
The lack of a consistent gap between net income and operating cash flow indicates that the company's losses are primarily driven by actual cash expenditures rather than non-cash accounting charges. Investors should monitor this alignment, as it confirms that the reported net loss is a reliable proxy for the actual cash depletion occurring within the R&D pipeline.
Based on the provided quarterly data, HOWL has consistently generated negative free cash flow, with quarterly outflows frequently exceeding $15 million, highlighting a trajectory that remains entirely dependent on external capital to sustain the ongoing clinical development of its INDUKINE platform through the next major data readouts.
The absence of positive free cash flow is expected for a clinical-stage entity, yet the magnitude of these outflows relative to the remaining cash balance warrants caution. This trend suggests that the company is in a high-burn phase, where the lack of commercial revenue forces a reliance on equity markets to fund operations.
According to recent SEC filings, working capital changes have shown significant quarterly volatility, ranging from a $4.6 million inflow to a $2.3 million outflow, which suggests that the timing of vendor payments and milestone-related accruals creates unpredictable short-term fluctuations in the company's available cash position.
This volatility implies that management's cash management is highly sensitive to the timing of clinical trial milestones and associated service provider invoices. Analysts should interpret these swings as a reflection of operational lumpy-ness rather than a fundamental shift in the company's underlying liquidity profile.
Financial data indicates that stock-based compensation, which reached $2.6 million in 2024Q2, serves as a non-cash expense that partially offsets the reported net loss, potentially obscuring the true economic cost of talent retention required to maintain the company's competitive edge in cytokine engineering.
While SBC is a standard tool for biotech talent acquisition, it represents a form of dilution that is not captured in the cash flow statement but remains a critical consideration for shareholders. The reliance on this non-cash compensation suggests that the company is managing its cash burn by shifting a portion of its compensation burden to equity-based instruments.
Quick answers to the most common questions about buying HOWL stock.
Werewolf Therapeutics, Inc. (HOWL) generated $-60.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Werewolf Therapeutics, Inc. (HOWL) reported negative free cash flow of $60.3M in 2025, indicating capital requirements exceeded cash from operations.
Werewolf Therapeutics, Inc. (HOWL) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.